Local treatment for metastatic prostate cancer: A systematic review

Derya Tilki, Raisa S. Pompe, Marco Bandini, Michele Marchioni, Alexander Kretschmer, Zhe Tian, Pierre I. Karakiewicz, Christopher P Evans

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The potential oncological benefit for radical treatment in the setting of oligometastatic prostate cancer has been under investigation and is frequently discussed. We carried out a systematic review of English language articles using the Medline database (January 2000 to May 2017) to identify studies reporting local treatment in men with metastatic prostate cancer at diagnosis. Primary end-points were oncological outcomes, such as cancer-specific and overall mortality. Secondary end-points were non-oncological outcomes, such as complications, operating room time, blood loss or length of hospital stay. Two independent authors reviewed and extracted all search results. Overall, 18 studies reporting on local treatment in metastatic prostate cancer patients were identified (14 original articles, three brief correspondences and one letter to the editor). All of them were retrospective; one partly included prospective data. All studies addressed oncological outcomes, 16 compared local treatment with no-local treatment and 14 adjusted for confounders using multivariable regression models. All but one study concluded a survival benefit for local treatment in the metastatic setting. Due to heterogeneity of available data, a representative meta-analysis could not be carried out. Five studies reported non-oncological outcomes. Although local treatment in metastatic prostate cancer appears to be feasible, its oncological effect remains unclear due to high susceptibility of available studies to significant selection bias.

Original languageEnglish (US)
JournalInternational Journal of Urology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Prostatic Neoplasms
Therapeutics
Length of Stay
Selection Bias
Operating Rooms
Meta-Analysis
Language
Databases
Survival
Mortality
Neoplasms

Keywords

  • Cytoreductive radical prostatectomy
  • Local treatment
  • Metastatic prostate cancer
  • Oligometastatic

ASJC Scopus subject areas

  • Urology

Cite this

Tilki, D., Pompe, R. S., Bandini, M., Marchioni, M., Kretschmer, A., Tian, Z., ... Evans, C. P. (Accepted/In press). Local treatment for metastatic prostate cancer: A systematic review. International Journal of Urology. https://doi.org/10.1111/iju.13535

Local treatment for metastatic prostate cancer : A systematic review. / Tilki, Derya; Pompe, Raisa S.; Bandini, Marco; Marchioni, Michele; Kretschmer, Alexander; Tian, Zhe; Karakiewicz, Pierre I.; Evans, Christopher P.

In: International Journal of Urology, 01.01.2018.

Research output: Contribution to journalArticle

Tilki, D, Pompe, RS, Bandini, M, Marchioni, M, Kretschmer, A, Tian, Z, Karakiewicz, PI & Evans, CP 2018, 'Local treatment for metastatic prostate cancer: A systematic review', International Journal of Urology. https://doi.org/10.1111/iju.13535
Tilki, Derya ; Pompe, Raisa S. ; Bandini, Marco ; Marchioni, Michele ; Kretschmer, Alexander ; Tian, Zhe ; Karakiewicz, Pierre I. ; Evans, Christopher P. / Local treatment for metastatic prostate cancer : A systematic review. In: International Journal of Urology. 2018.
@article{9457fe8804234c198c9b1eac3eb916a4,
title = "Local treatment for metastatic prostate cancer: A systematic review",
abstract = "The potential oncological benefit for radical treatment in the setting of oligometastatic prostate cancer has been under investigation and is frequently discussed. We carried out a systematic review of English language articles using the Medline database (January 2000 to May 2017) to identify studies reporting local treatment in men with metastatic prostate cancer at diagnosis. Primary end-points were oncological outcomes, such as cancer-specific and overall mortality. Secondary end-points were non-oncological outcomes, such as complications, operating room time, blood loss or length of hospital stay. Two independent authors reviewed and extracted all search results. Overall, 18 studies reporting on local treatment in metastatic prostate cancer patients were identified (14 original articles, three brief correspondences and one letter to the editor). All of them were retrospective; one partly included prospective data. All studies addressed oncological outcomes, 16 compared local treatment with no-local treatment and 14 adjusted for confounders using multivariable regression models. All but one study concluded a survival benefit for local treatment in the metastatic setting. Due to heterogeneity of available data, a representative meta-analysis could not be carried out. Five studies reported non-oncological outcomes. Although local treatment in metastatic prostate cancer appears to be feasible, its oncological effect remains unclear due to high susceptibility of available studies to significant selection bias.",
keywords = "Cytoreductive radical prostatectomy, Local treatment, Metastatic prostate cancer, Oligometastatic",
author = "Derya Tilki and Pompe, {Raisa S.} and Marco Bandini and Michele Marchioni and Alexander Kretschmer and Zhe Tian and Karakiewicz, {Pierre I.} and Evans, {Christopher P}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/iju.13535",
language = "English (US)",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Local treatment for metastatic prostate cancer

T2 - A systematic review

AU - Tilki, Derya

AU - Pompe, Raisa S.

AU - Bandini, Marco

AU - Marchioni, Michele

AU - Kretschmer, Alexander

AU - Tian, Zhe

AU - Karakiewicz, Pierre I.

AU - Evans, Christopher P

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The potential oncological benefit for radical treatment in the setting of oligometastatic prostate cancer has been under investigation and is frequently discussed. We carried out a systematic review of English language articles using the Medline database (January 2000 to May 2017) to identify studies reporting local treatment in men with metastatic prostate cancer at diagnosis. Primary end-points were oncological outcomes, such as cancer-specific and overall mortality. Secondary end-points were non-oncological outcomes, such as complications, operating room time, blood loss or length of hospital stay. Two independent authors reviewed and extracted all search results. Overall, 18 studies reporting on local treatment in metastatic prostate cancer patients were identified (14 original articles, three brief correspondences and one letter to the editor). All of them were retrospective; one partly included prospective data. All studies addressed oncological outcomes, 16 compared local treatment with no-local treatment and 14 adjusted for confounders using multivariable regression models. All but one study concluded a survival benefit for local treatment in the metastatic setting. Due to heterogeneity of available data, a representative meta-analysis could not be carried out. Five studies reported non-oncological outcomes. Although local treatment in metastatic prostate cancer appears to be feasible, its oncological effect remains unclear due to high susceptibility of available studies to significant selection bias.

AB - The potential oncological benefit for radical treatment in the setting of oligometastatic prostate cancer has been under investigation and is frequently discussed. We carried out a systematic review of English language articles using the Medline database (January 2000 to May 2017) to identify studies reporting local treatment in men with metastatic prostate cancer at diagnosis. Primary end-points were oncological outcomes, such as cancer-specific and overall mortality. Secondary end-points were non-oncological outcomes, such as complications, operating room time, blood loss or length of hospital stay. Two independent authors reviewed and extracted all search results. Overall, 18 studies reporting on local treatment in metastatic prostate cancer patients were identified (14 original articles, three brief correspondences and one letter to the editor). All of them were retrospective; one partly included prospective data. All studies addressed oncological outcomes, 16 compared local treatment with no-local treatment and 14 adjusted for confounders using multivariable regression models. All but one study concluded a survival benefit for local treatment in the metastatic setting. Due to heterogeneity of available data, a representative meta-analysis could not be carried out. Five studies reported non-oncological outcomes. Although local treatment in metastatic prostate cancer appears to be feasible, its oncological effect remains unclear due to high susceptibility of available studies to significant selection bias.

KW - Cytoreductive radical prostatectomy

KW - Local treatment

KW - Metastatic prostate cancer

KW - Oligometastatic

UR - http://www.scopus.com/inward/record.url?scp=85044304972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044304972&partnerID=8YFLogxK

U2 - 10.1111/iju.13535

DO - 10.1111/iju.13535

M3 - Article

C2 - 29572963

AN - SCOPUS:85044304972

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

ER -